The oncology nutrition market size is projected to be valued at US$ 2.07 billion in 2023 and is expected to be valued at US$ 4.87 billion by 2033. The demand for oncology nutrition is likely to record an average CAGR of 8.9% during the forecast period.
Medical nutrition therapy for cancer is crucial for enhancing physical capacity, coping with cancer therapies, and overall quality of life. For businesses functioning in contemporary oncology nutrition products, the fall in tolerance to cancer therapy is anticipated to boost the adoption of oncology nutrition. Furthermore, nutritional screening and evaluation are essential for identifying people who are more likely to be malnourished.
Oncology Nutrition Market Trend Analysis
| Report Attribute | Details |
|---|---|
| Oncology Nutrition Market Revenue (2023) | US$ 2.07 billion |
| Market Anticipated Forecast Value (2033) | US$ 4.87 billion |
| Market Projected Growth Rate (2023 to 2033) | 8.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Due to technological developments and extensive research, the cancer nutrition supplements market share is anticipated to expand significantly over the next few years. The demand for oncology nutrition is anticipated to pick up steam throughout the evaluation period, even if the nutritional risk is still mostly beneath the radar.
| Attributes | Details |
|---|---|
| Oncology Nutrition Market Size (2018) | US$ 1.33 billion |
| Market Size (2022) | US$ 1.92 billion |
| Market (CAGR 2018 to 2022) | 7.6% |
Due to the worldwide increase in cases of malnutrition brought on by tumors, oncology nutrition is still a crucial topic for healthcare professionals. According to several studies, malnutrition screening in cancer treatment could enhance nutritional evaluation and help patients avoid malnutrition.
Growth Driving Factors in the Oncology Nutrition Market
A significant driver of the cancer nutrition market's growth is projected to be the huge increase in nutritional waste and nutritional risk among cancer patients. Participants in the market landscape are now investigating the possible advantages of utilizing a multidisciplinary strategy, where focused oncology nutrition guidelines are expected to be crucial to improving the standard of cancer care.
The oncology nutrition companies are anticipated to profit from increased research and development activities as well as the launch of cutting-edge products for cancer patients over the forecasted period. The creation of essential formulas and the advent of new markets are also anticipated to boost the cancer nutrition patent landscape and the pace of future expansion.
Due to these factors, the overall market is anticipated to reach US$ 3.12 billion by the end of 2027. A few key aspects anticipated to drive the expansion of the market for oncology nutrition research in the upcoming years include:
Due to the considerable increase in the use of nutritional evaluation programs, particularly during cancer cachexia and pre-cachexia, the demand for oncology nutrition is predicted to continue to rise. Over the past ten years, data-gathering methods for varied patients' nutritional status have advanced quickly. These developments have led to personalized oncology nutrition therapy and are now recognized as the perfect remedy for cancer patients prone to malnutrition.
Principal Consultant
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The gastrointestinal cancer sector is expected to develop over the research period due to the high incidence of this cancer in the global population.
| Attributes | Details |
|---|---|
| Top Cancer Type | Gastrointestinal Cancer |
| Market Share in 2023 | 22.2% |
This situation has led to the growth of gastrointestinal cancer nutritional supplements and increased awareness of the importance of nutritional supplement use.
The demand for oncology nutrition is growing because diet provides the ability to fight disease and provides power and endurance against the treatment's side effects.
| Attributes | Details |
|---|---|
| Top Route of Administration Type | Enteral Nutrition |
| Market Share in 2023 | 73% |
As the number of individuals diagnosed with cancer rises, medical professionals will likely favor the enteral nutrition segment.
The requirement of appropriate medication strategy and prescriptions has resulted in higher sales of all nutrition and supplements market products through hospitals and clinic segments.
| Attributes | Details |
|---|---|
| Top Distribution Channel Type | Hospitals and Clinics |
| Market Share in 2023 | 46.8% |
So, as per our estimates, this segment is anticipated to remain the leading distribution channel for oncology nutrition products as well through 2033.
North America is anticipated to lead the global oncology nutrition market throughout the forecast period. This is due to several important factors, including the increased incidence of cancer and the accessibility of cutting-edge healthcare infrastructure.
The oncology nutrition market in the United States is expected to be worth around US$ 412.6 million. According to a statistic from the American Cancer Society, there will likely be 1.9 million new instances of cancer in the United States this year.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 33.4% |
| Europe | 28.8% |
FMI projects that the Asia Pacific oncology nutrition market is anticipated to expand faster due to the region's rising prevalence of cancer cases. Additionally, several certification programs and awareness sessions are held locally to inform cancer patients and healthcare professionals about the significance of oncology nutrition.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| United States | 29.7% |
| Germany | 7.9% |
| Japan | 3.4% |
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 8.3% |
| China | 11.9% |
| India | 9.4% |
| Australia | 9.6% |
With certain leading pharmaceutical corporations, startups in the oncology nutrition sector are working hard in this area. Clinical studies now include parenteral oncology feeding. Oncology nutrition is projected to become more popular as cancer incidence and the demand for tailored medication and nutrition rise.
In the market for cancer nutrition, collaboration with nutritionists and oncology research institutes is also anticipated to present considerable prospects for companies. For instance, the American biotechnology giant Celgene Corporation teamed up with Savor Health, a provider of specialized nutritional advice to cancer patients.
New product launches and continuous technological innovations are the key strategies adopted by prominent players in the oncology nutrition market. The healthcare systems organizations are changing due to new research and increased public knowledge of the advantages of oncology nutrition. Clinical nutritionists and oncologists are working more closely to improve oncology nutrition and treatment within the oncology nutrition sector.
The presence of competitors, new product debuts, and partnerships related to the industry under consideration all contribute to the market's growth. According to the report, Esperer launched its nutrition development center in Hyderabad in 2020. The facility in Hyderabad is expected to house a variety of cohesive capabilities, such as investigative workrooms and product development sub-centers, with a dedicated laboratory for analyzing sensory components, packing, and taste.
The leading firms worldwide for oncology nutrition are focused on obtaining regulatory clearances, developing cutting-edge goods, introducing new products, and partnering with and acquiring other businesses. The global market for oncology nutrition is projected to expand due to these leading players' tactics. The following are a few expansion methods used by companies in the oncology nutrition market:
| Attribute | Details |
|---|---|
| Growth Rate | CAGR of 8.9% from 2023 to 2033 |
| Base Year of Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and F-CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, growth factors, Trends, and Pricing Analysis |
| Key Segments Covered | By Cancer Type, By End Use, By Region |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; The Middle East & Africa; Oceania |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, Italy, France, United Kingdom, Spain, Russia, China, Japan, GCC Countries, Australia |
| Key Companies Profiled | FMC Corporation; Danone India; Abbott; Aceto; B. Braun Melsungen AG; Baxter; Fresenius Kabi AG; Global Health Products, Inc.; Hormel Foods Corporation; Mead Johnson & Company, LLC; Meiji Holdings Co., Ltd; Nestlé S.A.; BioSig Technologies, Inc.; Auris Health, Inc. |
The overall market is estimated to be around US$ 2.07 billion in 2023.
FMC, Danone, and Abbott are some of the leading market players.
Proper management of diet intake of patients undergoing cancer treatment.
The hospitals and clinical market segment contributed 46.8% of revenue in 2022.
Collaborations with nutritionists and oncology research institutes are driving the market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Cancer Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Cancer Type, 2023 to 2033 5.3.1. Head & Neck Cancer 5.3.2. Stomach & Gastrointestinal Cancers 5.3.3. Blood Cancer 5.3.4. Breast Cancer 5.3.5. Lung Cancer 5.3.6. Other cancers 5.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Cancer Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Use 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End Use, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Use, 2023 to 2033 6.3.1. Hospitals 6.3.2. Home Care 6.3.3. Others 6.4. Y-o-Y Growth Trend Analysis By End Use, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End Use, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. USA 8.2.1.2. Canada 8.2.2. By Cancer Type 8.2.3. By End Use 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Cancer Type 8.3.3. By End Use 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Cancer Type 9.2.3. By End Use 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Cancer Type 9.3.3. By End Use 9.4. Key Takeaways 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Cancer Type 10.2.3. By End Use 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Cancer Type 10.3.3. By End Use 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Cancer Type 11.2.3. By End Use 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Cancer Type 11.3.3. By End Use 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Cancer Type 12.2.3. By End Use 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Cancer Type 12.3.3. By End Use 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Cancer Type 13.2.3. By End Use 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Cancer Type 13.3.3. By End Use 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Cancer Type 14.2.3. By End Use 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Cancer Type 14.3.3. By End Use 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Cancer Type 15.1.2.2. By End Use 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Cancer Type 15.2.2.2. By End Use 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Cancer Type 15.3.2.2. By End Use 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Cancer Type 15.4.2.2. By End Use 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Cancer Type 15.5.2.2. By End Use 15.6. UK 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Cancer Type 15.6.2.2. By End Use 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Cancer Type 15.7.2.2. By End Use 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Cancer Type 15.8.2.2. By End Use 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Cancer Type 15.9.2.2. By End Use 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Cancer Type 15.10.2.2. By End Use 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Cancer Type 15.11.2.2. By End Use 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Cancer Type 15.12.2.2. By End Use 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Cancer Type 15.13.2.2. By End Use 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Cancer Type 15.14.2.2. By End Use 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Cancer Type 15.15.2.2. By End Use 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Cancer Type 15.16.2.2. By End Use 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Cancer Type 15.17.2.2. By End Use 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Cancer Type 15.18.2.2. By End Use 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Cancer Type 15.19.2.2. By End Use 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Cancer Type 15.20.2.2. By End Use 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Cancer Type 15.21.2.2. By End Use 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Cancer Type 15.22.2.2. By End Use 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2022 15.23.2.1. By Cancer Type 15.23.2.2. By End Use 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Cancer Type 16.3.3. By End Use 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. FMC Corporation 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Danone India 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Abbott 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Aceto 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. B. Braun Melsungen AG 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. Baxter 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Fresenius Kabi AG 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Global Health Products, Inc. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Hormel Foods Corporation 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Mead Johnson & Company, LLC 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 17.1.11. Meiji Holdings Co., Ltd 17.1.11.1. Overview 17.1.11.2. Product Portfolio 17.1.11.3. Profitability by Market Segments 17.1.11.4. Sales Footprint 17.1.11.5. Strategy Overview 17.1.11.5.1. Marketing Strategy 17.1.12. Nestlé S.A. 17.1.12.1. Overview 17.1.12.2. Product Portfolio 17.1.12.3. Profitability by Market Segments 17.1.12.4. Sales Footprint 17.1.12.5. Strategy Overview 17.1.12.5.1. Marketing Strategy 17.1.13. BioSig Technologies, Inc. 17.1.13.1. Overview 17.1.13.2. Product Portfolio 17.1.13.3. Profitability by Market Segments 17.1.13.4. Sales Footprint 17.1.13.5. Strategy Overview 17.1.13.5.1. Marketing Strategy 17.1.14. Auris Health, Inc. 17.1.14.1. Overview 17.1.14.2. Product Portfolio 17.1.14.3. Profitability by Market Segments 17.1.14.4. Sales Footprint 17.1.14.5. Strategy Overview 17.1.14.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Oncology Nutrition Market
